BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-14@catalystbrief.girapphe.com
DTSTAMP:20261117T061545Z
LAST-MODIFIED:20261117T061545Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Regeneron Pharmaceuticals — Fianlimab [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Trial to See if the Combination o
 f Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing
  or Delaying Melanoma From Coming Back After it Has Been Removed With Surg
 ery.\nSource: https://clinicaltrials.gov/study/NCT05608291\nhttps://cataly
 stbrief.girapphe.com/e/14?lang=en\nNot investment advice. Dates may change
 .
URL:https://catalystbrief.girapphe.com/e/14?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
